Immune Checkpoint Inhibitors Market by Type, Indication, Route of Administration, End-Users, Distribution Channel - Global Forecast 2025-2030- Product Image

Sale

Immune Checkpoint Inhibitors Market by Type, Indication, Route of Administration, End-Users, Distribution Channel - Global Forecast 2025-2030

Report
188 Pages
October 2024
Region: Global
360iResearch™
ID: 5888905

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The Immune Checkpoint Inhibitors Market grew from USD 9.47 billion in 2023 to USD 10.46 billion in 2024. It is expected to continue growing at a CAGR of 10.82%, reaching USD 19.46 billion by 2030.

The immune checkpoint inhibitors (ICIs) market is a dynamic segment within oncology therapeutics, focused on monoclonal antibodies that modulate the immune system to target cancer cells. The necessity for ICIs arises from the unmet need for effective cancer treatments, particularly in cases where traditional therapies like chemotherapy and radiation fall short. Applications primarily focus on advanced and metastatic cancers, including melanoma, lung, and urothelial carcinomas. The end-use scope predominantly involves hospitals and specialty cancer clinics that administer these sophisticated therapies. The market is heavily influenced by factors such as increasing cancer incidence, advances in biotechnological research, and strong governmental support for cancer treatments. The growing awareness and acceptance of immunotherapy contribute positively to the market's expansion. However, high treatment costs, limited accessibility in low-income regions, and potential immune-related adverse effects are significant challenges that could constrain growth. Recent opportunities lie in expanding indications for existing drugs and the development of combination therapies that enhance efficacy while minimizing adverse effects. Additionally, ongoing clinical trials present avenues for new product development and innovation. Businesses should focus on leveraging collaborations with academic research institutions to foster innovations in next-generation ICIs and explore personalized medicine applications, which hold promise in tailoring treatments to individual patients' immune profiles. Furthermore, the evolution of biomarkers may facilitate more precise patient selection, optimizing therapeutic outcomes. Nevertheless, the market nature demands overcoming regulatory hurdles and addressing the concerns of healthcare payers about the cost-effectiveness of these treatments. By navigating these challenges and capitalizing on trends toward personalized and precision medicine, stakeholders can achieve sustainable growth in this sector. Exploring immune-modulatory mechanisms and diverse cancer types can spur new research trajectories, adding breadth to existing therapeutic portfolios.

Understanding Market Dynamics in the Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of cancer across the globe
- Rising government initiatives for cancer treatment and awareness programs
- Growing geriatric population and adoption of unhealthy lifestyle
Market Restraints
- Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
Market Opportunities
- Ongoing research activities for advanced cancer treatments
- Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
Market Challenges
- Presence of alternative treatment therapies for cancer

Exploring Porter’s Five Forces for the Immune Checkpoint Inhibitors Market

Porter’s Five Forces framework further strengthens the insights of the Immune Checkpoint Inhibitors Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Immune Checkpoint Inhibitors Market

External macro-environmental factors deeply influence the performance of the Immune Checkpoint Inhibitors Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Immune Checkpoint Inhibitors Market

The Immune Checkpoint Inhibitors Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alphamab Oncolog, ALX Oncology Inc., Astellas Pharma Inc., AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., Kintor Pharmaceutical Limited, Merck KGaA, MiNK Therapeutics, Inc., NATCO Pharma Ltd., NextCure, Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Seagen Inc., SQZ Biotechnologies Company, Thermo Fisher Scientific Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
Indication
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Hodgkin Lymphoma
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Solid Cancer
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer across the globe
5.1.1.2. Rising government initiatives for cancer treatment and awareness programs
5.1.1.3. Growing geriatric population and adoption of unhealthy lifestyle
5.1.2. Restraints
5.1.2.1. Associated side effects, high cost and efficacy concerns of immune checkpoint inhibitors
5.1.3. Opportunities
5.1.3.1. Ongoing research activities for advanced cancer treatments
5.1.3.2. Rise in approvals of novel immune checkpoint inhibitors from regulatory bodies
5.1.4. Challenges
5.1.4.1. Presence of alternative treatment therapies for cancer
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Immune Checkpoint Inhibitors Market, by Type

6.1. Introduction
6.2. CTLA-4 Inhibitor
6.3. PD-1 Inhibitor
6.4. PD-L1 Inhibitor

7. Immune Checkpoint Inhibitors Market, by Indication

7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Hodgkin Lymphoma
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Solid Cancer

8. Immune Checkpoint Inhibitors Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Immune Checkpoint Inhibitors Market, by End-Users

9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics

10. Immune Checkpoint Inhibitors Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies

11. Americas Immune Checkpoint Inhibitors Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Immune Checkpoint Inhibitors Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Immune Checkpoint Inhibitors Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. IMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. IMMUNE CHECKPOINT INHIBITORS MARKET DYNAMICS
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SOLID CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 50. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 82. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 92. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 122. THAILAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. DENMARK IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 143. EGYPT IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 148. FINLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 168. ITALY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 188. POLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 193. QATAR IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 240. IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Immune Checkpoint Inhibitors Market, which are profiled in this report, include:

Alphamab Oncolog
ALX Oncology Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb
Dr. Reddy’s Laboratories Ltd.
F. Hoffmann-La Roche AG
Genmab A/S
GlaxoSmithKline PLC
ImmuneSensor Therapeutics Inc.
ImmunityBio, Inc.
Kintor Pharmaceutical Limited
Merck KGaA
MiNK Therapeutics, Inc.
NATCO Pharma Ltd.
NextCure, Inc.
Regeneron Pharmaceuticals Inc.
Sanofi SA
Seagen Inc.
SQZ Biotechnologies Company
Thermo Fisher Scientific Inc.
Xencor, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	188
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 10.46 Billion
Forecasted Market Value ( USD ) by 2030	$ 19.46 Billion
Compound Annual Growth Rate	10.8%
Regions Covered	Global
No. of Companies Mentioned	26

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the Immune Checkpoint Inhibitors Market

Exploring Porter’s Five Forces for the Immune Checkpoint Inhibitors Market

Applying PESTLE Analysis to the Immune Checkpoint Inhibitors Market

Analyzing Market Share in the Immune Checkpoint Inhibitors Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Immune Checkpoint Inhibitors Market

Strategic Recommendations for Success in the Immune Checkpoint Inhibitors Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast Cancer, Melanoma), Distribution Channel, Region, and Segment Forecasts, 2024-2030

Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030

Immune Checkpoint Inhibitors - Global Strategic Business Report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2024-2032

About the Immune Checkpoint Inhibitor Market